Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: Lilly’s India manufacturing bet locks in low-cost production muscle, outflanking China-dependent rivals as Mounjaro mania drives capacit...
Key Highlights: Implications: Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access. Dual T2D/weight...
Latest Developments in Peptide-Based Medicines Peptide-based drugs are gaining significant attention in the global pharmaceutical industry due to their ability to target specific biological path...
